Employees: 645
Size Peptidream (4587.T) is a Japan Health Care company (Biotechnology) with a market value of $878M, the 804th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,089 on 18 Nov 2026.
Performance Over six months the shares fell 3.4%, against -17.4% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 14.2% over the last twelve months (peer median +0.6%); the operating margin is -18.4% (peer median -28.8%).
Valuation It trades at 29.9× forward earnings against a peer median of 35.0× (4th cheapest of 7).
Capital Return on invested capital runs 11.1 points below its cost of capital (5.0% WACC).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥20.5B | ¥18.5B | ¥46.7B | ¥28.7B | ¥26.9B |
| Revenue growth | — | -60% | +63% | +7% | — |
| Gross profit | ¥9.65B | ¥7.20B | ¥34.2B | ¥16.9B | ¥17.8B |
| EBITDA | -¥1.77B | -¥2.85B | ¥23.6B | ¥9.61B | ¥11.3B |
| Net income | -¥2.89B | -¥3.75B | ¥15.0B | ¥3.04B | ¥7.55B |
| Free cash flow | -¥5.93B | -¥15.0B | ¥21.8B | ¥11.2B | -¥4.02B |
| Capital expenditure | ¥1.50B | ¥1.75B | ¥2.22B | ¥1.37B | ¥3.98B |
| Total debt | ¥15.0B | ¥19.5B | ¥20.4B | ¥22.8B | ¥21.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4587.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.8% | -8.2% | 5th highest of 21 |
| 6-month return | -3.4% | -17.4% | 6th highest of 21 |
| Distance from 52-week high | -39.3% | -41.8% | 9th highest of 21 |
| Revenue growth (TTM) | +14.2% | +0.6% | 7th highest of 17 |
| Operating margin | -18.4% | -28.8% | 8th highest of 18 |
| Forward P/E | 29.9× | 35.0× | 4th cheapest of 7 |
| ROIC minus cost of capital | -11.1 pp | -9.5 pp | 7th highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 29.9× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | n/a | n/a | n/a |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 143.0× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 21.6× | 9.2% | +2.3% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | n/a | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 92.6× | 39.6% | -16.6% |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 41.5× | 6.1% | +4.4% |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | n/a | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 19.4× | 7.8% | +2.4% |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | n/a | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | n/a | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | n/a | n/a | n/a |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | n/a | -13.5% | -10.9% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 28.4× | 14.3% | -5.8% |